Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center
mi
from
Dallas, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
El Paso Cancer Treatment Center
mi
from
El Paso, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
El Paso Cancer Treatment Center
mi
from
El Paso, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
UT MD Anderson Cancer Center
mi
from
Houston, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Allison Cancer Center
mi
from
Midland, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
US Oncology
mi
from
Plano, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
US Oncology
mi
from
Plano, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
HOAST
mi
from
San Antonio, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
HOAST
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Tyler Cancer Center
mi
from
Tyler, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Texas Oncology
mi
from
Waco, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Texas Oncology
mi
from
Waco, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Mater Private Medical Centre - Haematology and Oncology Clinics of Australasia Research Centre
mi
from
South Brisbane,
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Mater Private Medical Centre - Haematology and Oncology Clinics of Australasia Research Centre
mi
from
South Brisbane,
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
St Joseph Oncology
mi
from
Saint Joseph, MO
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
St Joseph Oncology
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Arch Medical Services
mi
from
Saint Louis, MO
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Arch Medical Services
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study for Patients With Non-Hodgkin's Lymphomas
A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas
Status: Enrolling
Updated:  4/9/2018
Clinical Research Facility
mi
from
Anaheim, CA
A Study for Patients With Non-Hodgkin's Lymphomas
A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas
Status: Enrolling
Updated: 4/9/2018
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated:  4/10/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
Status: Enrolling
Updated: 4/10/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
City of Hope South Pasadena
mi
from
South Pasadena, CA
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated:  4/10/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma
Status: Enrolling
Updated: 4/10/2018
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
mi
from
Chapel Hill, NC
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Case Western Reserve University / University Hospitals Case Medical Center
mi
from
Cleveland, OH
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Case Western Reserve University / University Hospitals Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
University of Pennsylvania - Perelman Center for Advanced Medicine
mi
from
Philadelphia, PA
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
University of Pennsylvania - Perelman Center for Advanced Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Methodist Cancer Center
mi
from
Houston, TX
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Methodist Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Seattle Cancer Care Alliance / University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated:  4/18/2018
Northwest Cancer Specialists
mi
from
Vancouver, WA
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Status: Enrolling
Updated: 4/18/2018
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated:  4/18/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Status: Enrolling
Updated: 4/18/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/19/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/19/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/19/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/19/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/19/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/19/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/19/2018
Vanderbilt-Ingram Cancer Center, Vanderbilt University
mi
from
Nashville, TN
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/19/2018
Vanderbilt-Ingram Cancer Center, Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/19/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/19/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials